Eurobio Scientific / CareDx Lab Products business

Solid Organ and Stem Cell Transplantation (HLA Typing & Monitoring)

69K US cases/yr · $1.4B US Market · ~58% North America share of global transplant diagnostics market

Disease Overview

Solid organ and stem cell transplantation requires precise human leukocyte antigen (HLA) matching between donor and recipient to minimize rejection and graft-versus-host disease. HLA typing is performed on every potential donor (deceased and living) and every transplant recipient using molecular methods - real-time PCR for rapid deceased-donor typing (where time-to-organ-allocation is critical) and next-generation sequencing (NGS) for high-resolution recipient typing. Post-transplant, donor-derived cell-free DNA (dd-cfDNA) and chimerism monitoring assays detect early rejection or relapse, enabling intervention before clinical deterioration. Annually in the US, approximately 46,000 solid organ transplants and 23,000 hematopoietic stem cell transplants are performed, with each procedure requiring multiple HLA typing and post-transplant monitoring tests. Globally the number is roughly 3-4x higher. The market is mature and oligopolistic, with Thermo Fisher (One Lambda), CareDx, Omixon, Illumina (with NGS instrumentation), and Eurobio/GenDx as the principal players. Unmet need centers on faster turnaround for deceased-donor allocation, higher resolution typing to reduce mismatch-related complications, and non-invasive monitoring to replace surveillance biopsies.

Competitive Landscape

Transplant diagnostics is a consolidated market dominated by Thermo Fisher's One Lambda (the global leader in HLA typing reagents and software), CareDx (transitioning out of Lab Products to focus on AlloSure dd-cfDNA testing services), Omixon, Illumina (NGS platforms used by all kit makers), and the Eurobio/GenDx franchise. Eurobio's 2020 acquisition of GenDx established it as the European NGS HLA typing leader; the CareDx Lab Products acquisition adds CareDx AB (Sweden), real-time PCR kits for rapid deceased-donor typing, complementary NGS HLA assays, and ex-North America NGS post-transplant monitoring rights - creating a vertically integrated transplant diagnostics platform spanning pre-transplant typing through post-transplant monitoring. CareDx retains exclusive perpetual North American distribution rights for its post-transplant monitoring tests including AlloSeq cfDNA. Five-to-ten years post-close, Eurobio's success hinges on cross-selling integrated kit-plus-software offerings to consolidating European and APAC transplant labs while defending against Thermo Fisher's scale; for CareDx, success means accelerating AlloSure/AlloMap services growth and disciplined capital deployment of the $170M proceeds.